Physician profile
Charles Parrish
NPI 1861481400
$4,727.26
in general payments reported to CMS, 2019-2025
28 companies · $789 in 2025
The $789 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $290 · 2021: $831 · 2022: $561 · 2023: $619 · 2024: $1,083 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Gift: $40.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.36 |
| Gift | $40.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.48 | 2019-2025 | |
| Braintree Laboratories, INC. | $514.04 | 2019-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $447.06 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $343.76 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $320.80 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $307.41 | 2022-2025 | Dupixent |
| Pfizer INC. | $249.51 | 2019-2025 | |
| Janssen Biotech, INC. | $199.15 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $196.38 | 2019-2024 | Rebyota |
| Genzyme Corporation | $180.46 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $178.16 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.30 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $134.29 | 2023-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $111.07 | 2024 | Ibsrela |
| Amgen INC. | $65.58 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $65.14 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $49.32 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $41.81 | 2025 | Wegovy |
| Gilead Sciences, INC. | $35.27 | 2021 | |
| Merck Sharp & Dohme LLC | $27.32 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $23.87 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $23.69 | 2021 | |
| Lilly USA, LLC | $22.86 | 2023 | |
| Aimmune Therapeutics, INC. | $19.28 | 2025 | Zenpep |
| Allergan, INC. | $17.13 | 2019 | |
| Medline Industries Lp | $16.89 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.19 | 2024 | Voquezna |
| Concordia Pharmaceuticals INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.